Literature DB >> 2196903

Expression and characterization of human CD4:immunoglobulin fusion proteins.

G Zettlmeissl1, J P Gregersen, J M Duport, S Mehdi, G Reiner, B Seed.   

Abstract

Different chimeric antibody-like molecules consisting of the four human CD4 extracellular domains (amino acids 1-369) fused to different parts of human IgG1 and IgM heavy-chain constant regions have been created and expressed in mammalian cells. For both IgG1 and IgM fusion proteins, the best expression in COS cells was observed for molecules lacking the CH1 domain of the heavy-chain constant region. The chimeric molecules are potent inhibitors of human immunodeficiency virus (HIV) infection and HIV-mediated cytotoxicity. A CD4:IgG1 hinge fusion protein, which was analyzed in more detail, binds efficiently to HIV gp160 and human Fc receptors and shows complement-assisted inhibition of viral propagation in culture. Half-life studies after intravenous application of the latter human fusion protein into mice and monkeys showed significant prolongation of serum survival compared to soluble CD4. An IgG2b murine homolog of the human CD4:IgG1 hinge fusion protein was prepared and evaluated in mice, where it was found to be nontoxic and to have no detectable effect on the humoral response to soluble antigen.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2196903     DOI: 10.1089/dna.1990.9.347

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  16 in total

1.  A CD 4: immunoglobulin fusion protein with antiviral effects against HIV.

Authors:  J P Gregersen; S Mehdi; H Gelderblom; G Zettlmeissl
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

2.  Hematopoietic activity of a stromal cell transmembrane protein containing epidermal growth factor-like repeat motifs.

Authors:  K A Moore; B Pytowski; L Witte; D Hicklin; I R Lemischka
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

3.  Biological and pharmacokinetic properties of a novel immunoglobulin-CD4 fusion protein.

Authors:  J B Lyczak; S L Morrison
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

4.  Antiretroviral cytolytic T-lymphocyte nonresponsiveness: FasL/Fas-mediated inhibition of CD4(+) and CD8(+) antiviral T cells by viral antigen-positive veto cells.

Authors:  R F Rich; W R Green
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

5.  Binding of gastrointestinal tumor cells to endothelial E- and P-selectin adhesion receptors leads to transient down-regulation of sLeX ligands in vitro.

Authors:  Horst Schuldes; Daniel Schleicher; Gottfried Mayer; Bernd H Markus; Jindrich Cinatl; Roman A Blaheta
Journal:  Int J Colorectal Dis       Date:  2003-02-01       Impact factor: 2.571

6.  Lectin-like oxidized low-density lipoprotein receptor 1 mediates phagocytosis of aged/apoptotic cells in endothelial cells.

Authors:  K Oka; T Sawamura; K Kikuta; S Itokawa; N Kume; T Kita; T Masaki
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

7.  Recombinant soluble interleukin-4 (IL-4) receptor acts as an antagonist of IL-4 in murine cutaneous Leishmaniasis.

Authors:  A Gessner; K Schröppel; A Will; K H Enssle; L Lauffer; M Röllinghoff
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

8.  Novel mode of action of the calcium antagonist mibefradil (Ro 40-5967): potent immunosuppression by inhibition of T-cell infiltration through allogeneic endothelium.

Authors:  R A Blaheta; N P Hailer; N Brude; B Wittig; E Oppermann; K Leckel; S Harder; M Scholz; S Weber; A Encke; B H Markus
Journal:  Immunology       Date:  1998-06       Impact factor: 7.397

9.  Direct expression and validation of phage-selected peptide variants in mammalian cells.

Authors:  Brian D Quinlan; Matthew R Gardner; Vinita R Joshi; Jessica J Chiang; Michael Farzan
Journal:  J Biol Chem       Date:  2013-05-10       Impact factor: 5.157

10.  Antiviral effects of different CD4-immunoglobulin constructs against HIV-1 and SIV: immunological characterization, pharmacokinetic data and in vivo experiments.

Authors:  K D Langner; M Niedrig; P Fultz; D Anderson; G Reiner; H Repke; H Gelderblom; B Seed; J Hilfenhaus; G Zettlmeissl
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.